In an effort to ramp up the speed of vaccination in the country, the Union Health Ministry has approved another laboratory for testing and lot release of COVID-19 vaccines, it said on Monday.
The ministry has notified the National Institute of Animal Biotechnology (NIAB) as a Central Drug Laboratory (CDL) for testing and lot release of Covid vaccines, according to an official statement.
In order to discuss the various aspects of COVID-19 vaccination distribution in India, a meeting was organised under the chairmanship of the cabinet secretary on November 11, 2020.
In the meeting, the Department of Biotechnology (DBT), Department of Science and Technology (DST), and the Council of Scientific and Industrial Research (CSIR) were asked to indicate to the Health Ministry if any of their labs could be converted for use as a CDL.
After due deliberations, the DBT proposed two laboratories, namely the NIAB and the National Centre for Cell Sciences (NCCS), Pune, for this purpose. Funds from the Prime Minister Cares Fund Trust (PM-CARES) were allotted for upgradation of these two laboratories, the statement said.
"The Central Drugs Standard Control Organisation (CDSCO) had furnished a draft notification to the Union Health Ministry for notifying NIAB, Hyderabad as a CDL laboratory in response to which the Union Health Ministry has now notified NIAB, Hyderabad as a CDL laboratory," it added.
The NCCS, Pune was notified as a CDL on June 28, 2021 by the Health Ministry, the statement said.
The notification of these two laboratories as CDLs will improve vaccine production and ultimately strengthen the vaccination campaign, it stated.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)